{
    "Trade/Device Name(s)": [
        "ADVIA Centaur\u00ae TSH3-Ultra II (TSH3ULII)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K233050",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083844",
        "K150403"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JLW"
    ],
    "Summary Letter Date": "March 1, 2024",
    "Summary Letter Received Date": "March 1, 2024",
    "Submission Date": "September 25, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1690"
    ],
    "Regulation Name(s)": [
        "Thyroid Stimulating Hormone Test System"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Thyroid-stimulating hormone (TSH, thyrotropin)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur\u00ae XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Direct chemiluminescent",
        "Immunologic sandwich assay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur TSH3-Ultra II quantitative chemiluminescent immunoassay for thyroid-stimulating hormone measurement using ADVIA Centaur XP system",
    "Indications for Use Summary": "Quantitative determination of thyroid-stimulating hormone (TSH, thyrotropin) in human serum and plasma (EDTA and lithium heparin) to aid in diagnosis of thyroid or pituitary disorders",
    "fda_folder": "Clinical Chemistry"
}